Literature DB >> 6606259

Morphological transformation of human adenoviruses is determined to a large extent by gene products of region E1a.

P J van den Elsen, A Houweling, A J van der Eb.   

Abstract

The role of region E1a and E1b of human adenovirus (Ad) types 5 and 12 in determining the morphology of transformed colonies has been studied. Primary baby rat kidney cells were transfected with a mixture of plasmids containing Ad5 region E1a and Ad12 region E1b, or vice versa, and the morphology of the resulting transformed colonies was studied. It was found that the morphology of the colonies was correlated with the identity of the E1a region present in the cells; i.e., colonies transformed by Ad5 E1a plus Ad12 E1b resembled Ad5-transformed colonies, whereas those transformed by Ad12 E1a plus Ad5E1b resembled Ad12-transformed colonies. This suggested that the morphology of Ad-transformed cells is determined mainly by region E1a. To exclude the possibility that this phenomenon is due to an E1a-mediated and serotype-specific regulation of E1b expression and that the transformed phenotype is largely determined by region E1b, the experiments were repeated with Ad5 E1b plasmids in which the transcription regulation sequences had been replaced by the SV40 early promoter segment. In these plasmids E1b expression has become independent of region E1a. Foci of cells transformed by these E1b-SV40 promoter plasmids in the presence of either E1a of Ad5 or E1a of Ad12 again showed the same phenomenon, i.e., an Ad5-specific morphology with Ad5 E1a and Ad12-specific morphology with Ad12 E1a. Preliminary evidence showing that region E1b may regulate the concentration of E1a transcripts is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6606259     DOI: 10.1016/0042-6822(83)90549-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

Review 1.  Expression and interactions of human adenovirus oncoproteins.

Authors:  P A Boulanger; G E Blair
Journal:  Biochem J       Date:  1991-04-15       Impact factor: 3.857

Review 2.  Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation.

Authors:  Andrew N Blackford; Roger J A Grand
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

3.  Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins.

Authors:  E White; R Cipriani; P Sabbatini; A Denton
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

4.  p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection.

Authors:  F D Goodrum; D A Ornelles
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

5.  Adenovirus E1A downregulates cJun- and JunB-mediated transcription by targeting their coactivator p300.

Authors:  J S Lee; R H See; T Deng; Y Shi
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

6.  The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle.

Authors:  F D Goodrum; D A Ornelles
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Identification of adenovirus type 2 early region 1B proteins that share the same amino terminus as do the 495R and 155R proteins.

Authors:  J B Lewis; C W Anderson
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

8.  Immortalization by c-myc, H-ras, and Ela oncogenes induces differential cellular gene expression and growth factor responses.

Authors:  A Kelekar; M D Cole
Journal:  Mol Cell Biol       Date:  1987-11       Impact factor: 4.272

Review 9.  The structure and functions of the adenovirus early region 1 proteins.

Authors:  R J Grand
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

10.  Complementary functions of E1a conserved region 1 cooperate with conserved region 3 to activate adenovirus serotype 5 early promoters.

Authors:  H K Wong; E B Ziff
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.